← Leaderboards
Paul J Pockros
Scripps Research Institute
$218,896
Attributed
$218,896
Total exposure
13
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$218,896 · 13
By mechanism
M01$218,896 · 13
Top collaborators
No co-investigators on record.
Most similar at Scripps Research Institute
Same institution · by research overlap
- Francis Vincent Chisari$28,451,545
- John G. McHutchison$191,527
- Matthias G. Von Herrath$21,559,291
- Joel N Buxbaum$11,182,027
- Luca G. Guidotti$5,185,864
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchHuman Therapy EvaluationHepatitis CMicroorganism Disease ChemotherapyLiver Disorder ChemotherapyDrug Screening /EvaluationInterferon AlphaImmunotherapyPolyethylene GlycolsChronic Disease /DisorderInterferonsDrug Administration Rate /DurationRibavirinLongitudinal Human StudyHepatitis C VirusRecombinant ProteinsCombination ChemotherapyPharmacokineticsLiver CirrhosisAntiviral AgentsLiver PharmacologyAntiulcer DrugArginine Vasopressin
Grant awards (24)
PEG INTERFERON ALPHA 2A FOR CHRONIC HEPATITIS C$0
M01 · FY2002 · RR
FAMCYCLOVIR FOR WILD TYPE (HBEAG+) HEPATITIS B$0
M01 · FY2002 · RR
PEG-IFN VS ROFERON A IN NONCIRRHOTIC HEPATITIS C$0
M01 · FY2002 · RR
PEG IFN VS ROFERON A FOR CHRONIC HEPATITIS C WITH CIRRHOSIS$0
M01 · FY2002 · RR
VPA 985 IN LIVER CIRRHOSIS &ASCITES$0
M01 · FY2002 · RR
ALFACON 1 INDUCTION COMPARED TO STANDARD THERAPY IN HEPATITIS C VIRUS$0
M01 · FY2002 · RR
RHIL 12 FOR CHRONIC HEPATITIS C NON RESPONSIVE TO INTERFERON$0
M01 · FY2002 · RR
ORAL PANTOPRAZOLE IN PATIENTS WITH HEPATIC IMPAIRMENT$0
M01 · FY2002 · RR
RIBAVIRIN PLUS INFERGEN FOR NAIVE CHRONIC HEPATITIS C$0
M01 · FY2002 · RR
RIBAVIRIN IN CHRONIC HEPATITIS C IN COMB WITH PEG INTERF$0
M01 · FY2002 · RR
INTERFERON ALFACON 1IN CHRONIC HEPATITIS C$0
M01 · FY2002 · RR
RHIL 12 FOR CHRONIC HEPATITIS C NON RESPONSIVE TO INTERFERON$27,369
M01 · FY2000 · RR
OPEN LABEL CONSENSUS INTERFERON IN HEPATITIS C$27,361
M01 · FY2000 · RR
FAMCYCLOVIR FOR WILD TYPE (HBEAG+) HEPATITIS B$27,361
M01 · FY2000 · RR
SCREENING PROCEDURES FOR IDENTIFICATION OF PATIENTS FOR PROTOCOLS$27,361
M01 · FY2000 · RR
PEG-IFN VS ROFERON A IN NONCIRRHOTIC HEPATITIS C$27,361
M01 · FY2000 · RR
PEG IFN VS ROFERON A FOR CHRONIC HEPATITIS C WITH CIRRHOSIS$27,361
M01 · FY2000 · RR
VPA 985 IN LIVER CIRRHOSIS &ASCITES$27,361
M01 · FY2000 · RR
ALFACON 1 INDUCTION COMPARED TO STANDARD THERAPY IN HEPATITIS C VIRUS$27,361
M01 · FY2000 · RR
RIBAVIRIN PLUS INFERGEN FOR NAIVE CHRONIC HEPATITIS C$0
M01 · FY2000 · RR
RIBAVIRIN IN CHRONIC HEPATITIS C IN COMB WITH PEG INTERF$0
M01 · FY2000 · RR
INTERFERON ALFACON 1IN CHRONIC HEPATITIS C$0
M01 · FY2000 · RR
PEG INTERFERON ALPHA 2A FOR CHRONIC HEPATITIS C$0
M01 · FY2000 · RR
ORAL PANTOPRAZOLE IN PATIENTS WITH HEPATIC IMPAIRMENT$0
M01 · FY2000 · RR